Bayer - BAYN - ISIN: DE000BAY0017

[Tdv]

Bayer komt met nieuwe feromoontoepassing in fruit

Bayer gaat feromoonproducten van het Franse bedrijf M2i in de vorm van silicoonspuiten op de Nederlandse markt brengen.

De gewasbeschermingsmiddelenfabrikant heeft een exclusief contract gesloten met het Franse M2i, distributeur en producent van innovatieve, op feromoon gebaseerde biologische producten. Het betreft producten gericht op (mot) plagen in gewassen zoals steen- en pitvruchten, tomaten en druiven. De feromoonproducten vormen een aanvulling op de bestaande biologische portfolio van Bayer.

Geen residu
Voor feromoonvallen zijn verschillende toepassingen al te koop in Nederland, ook van afstand te besturen modellen op perslucht. Het voordeel van deze nieuwe toepassing is het uitblijven van residu, laat Bayer weten desgevraagd.

De producten van M2i betekenen een nieuwe toepassing van feromoonvallen met feitelijk een siliconenspuit. Voor de middelen bestaat nu nog geen toelating in Nederland, maar Bayer verwacht dat in één of twee jaar te hebben afgerond.

Dealer kiezen
Door de nieuwe toepassing wordt de markttoegang nog nader bepaald. Gebeurt dat met één exclusieve distributeur die de toepassing leert gebruiken, of gebeurt dat breder. Dat wordt nog onderzocht, stelt een woordvoerder.

Ook hier wil Bayer de producten koppelen aan digitale monitoringtoepassingen. Feromonen vormen een efficiënte en economische manier van gewasbescherming, omdat ze selectief en niet-toxisch zijn. Ook voorkmen ze op natuurlijke wijze de ontwikkeling van resistentie.

[Tdv]

Bayer Aktiengesellschaft: William N. Anderson to succeed Werner Baumann as Chairman of the Board of Management of Bayer AG

Leverkusen, February 8, 2023

Effective June 1, 2023, William N. (Bill) Anderson will become the new Chairman of the Board of Management of Bayer AG. This was decided by the company’s Supervisory Board at its meeting today. Before assuming the position of Chairman of the Board, Bill Anderson will join the Board of Management of Bayer AG on April 1st, 2023. The change of personnel in the position is the result of a diligent search and selection process that was kicked off mid last year.
Bill Anderson is a chemical engineer by education and has most recently served as CEO of Roche’s Pharmaceuticals Division. He will follow current CEO Werner Baumann, whose contract was originally scheduled to run until April 30, 2024. Werner Baumann will work closely with Bill Anderson to ensure a smooth transition process before retiring from Bayer end of May 2023.

[nobody]

Analysis: Bayer's new CEO has a full in-tray as investors push for change

FRANKFURT (Reuters) - Bayer's incoming CEO is inheriting a full in-tray from his predecessor: Thousands of lawsuits claiming its weedkiller causes cancer, an underwhelming drug development pipeline and disgruntled investors looking for major change.

Top investors, including mutual funds group Deka, are among those to have complained that Bayer's sagging shares have been burdened by a lack of trust in the company's leadership, with others reckoning one easy fix would be to separate the healthcare and agricultural businesses.

Bayer on Wednesday named long-time Roche executive Bill Anderson for the top job after months of shareholder pressure to remove embattled CEO Werner Baumann, who had previously said he would hold on until the end of his current term in April 2024.

The nearly 160-year-old German company's Frankfurt shares rallied to their highest since June as investors welcomed the change, underscoring the depth of frustration about Baumann's lack of responsiveness to the concerns of major shareholders.

"The most important task for Bill Anderson is to regain investors' trust," said Markus Manns, a portfolio manager at Germany's Union Investment, a top 20 shareholder.

He added that Anderson would also need to reconsider the group's structure and strengthen the drug development pipeline.

Bayer's shares lag those of its global rivals, having fallen about 40% - knocking about 30 billion euros off its market valuation - since it bought Monsanto in 2018 for about $63 billion.

Concerns about litigation over weedkiller Roundup continue to weigh on the share price, despite a recent string of courtroom victories, an improvement in the Crop Science unit's profit last year and better prospects in drug development.

BREAK-UP, STOCK UP?

Baumann's early exit has stirred debate about what the 56-year-old Anderson can do to restore investor trust and boost Bayer's shares.

The American is an accomplished drug industry leader, particularly in oncology and ophthalmology, where Bayer has development ambitions.

"This may generate optimism from investors looking for an improvement in the Pharma business," Credit Suisse analysts said.

But some investors, including activist Bluebell which disclosed it had bought a stake in Bayer last month, have demanded the sale or spin-off of the consumer health unit, which makes Aspirin painkillers and Clarityn allergy relief.

They say it's a relatively quick way to remove at least some of the conglomerate discount, estimated by Credit Suisse on Wednesday at 40%.

More of the discount could be eliminated by a separation of the much larger pharmaceutical and agriculture divisions because most money managers regard pure-play stocks as more attractive.

JP Morgan said early last month, when the shares were trading at around 49 euros, that Bayer stock was about 36% cheaper than the sum of the value of its parts of 76 euros per share.

Investment bankers say a separate listing or even the relocation to the United States of the Crop Science division, with 20 billion euros in 2021 sales, could give that unit's shares a further boost.

They cite a more investor-friendly jurisdiction and specialised U.S. money managers who are more appreciative of the agribusiness, which generates most of its sales in the Americas.

PHARMA STANDALONE

Political sources and industry experts say moving the Crop Science division abroad would create fears of job cuts at home. A stand-alone pharmaceuticals business, with 18.3 billion euros in 2021 sales, could also become a takeover target.

Labour representatives on Bayer's supervisory board, which have a say in strategic decisions thanks to Germany's co-determination laws, on Thursday weighed in against a break-up.

But political intervention would likely be limited to efforts to save jobs rather than standing in the way of a deal for one of Germany's oldest companies, the sources said.

Large takeovers have also become rare in the drug industry, with the exception of AstraZeneca's $39 billion purchase of Axelion in 2021.

"Megamergers are not so much on the agenda any more," said Mark Seidler, chief executive officer of consultancy firm Strategic Decisions Group.

Uncertainty over promising new drug technologies made buyers look for a string of smaller assets to hedge their bets on future blockbuster drugs instead, he added.

(Additional reporting by Matthias Inverardi; Editing by Josephine Mason and Kirsten Donovan)

By Ludwig Burger and Patricia Weiss

© Reuters 2023

https://www.marketscreener.com/news/lat ... ountview=0

[nobody]

Brazil Supreme Court rules Bayer must return $252 million in GMO soy royalties

SAO PAULO (Reuters) - Germany's Bayer has been ordered by Brazil's Supreme Court to return to Brazilian soybean farmers the royalties they were charged for a GMO soybean seed, the Mato Grosso farmer lobby Aprosoja-MT said in a statement on Friday.

The Feb. 13 ruling by Supreme Court Justice Nunes Marques relates to a GMO technology commercially known as Intacta RR2 Pro, created by Monsanto, which was later acquired by Germany's Bayer.

Bayer said in a statement it will determine its next steps while noting it would comply with the ruling.

The ruling is the latest chapter of a protracted battle opposing the crop science firm and Brazilian farmers, who have launched multiple legal challenges against the firm.

In 2017, Mato Grosso farmers sued Monsanto over that same genetically modified seed, seeking to cancel its patent protections by claiming it did not bring any technological innovation.

Two years later soy producer associations in 10 Brazilian states joined that lawsuit.

Aprosoja-MT said that according to the ruling, Bayer will now have to deposit 1.3 billion reais ($252 million) in an escrow account to return royalties paid by farmers going back to 2018.

Bayer said it is analyzing the Marques ruling, which refers specifically to a lawsuit brought by farmers claiming the company was charging royalties on a patent that had expired.

"It is worth mentioning that the Intacta RR2 Pro technology is protected by intellectual property rights of a wide and diverse nature," Bayer said. "We trust that these rights give us legal support so that the use of our protected technology is respected in the country."

A lawyer for Aprosoja-MT said Bayer can appeal Marques' ruling at the plenary of the Supreme Court.

Brazilian cotton producers have also sued Bayer over Bollgard II RR Flex genetically modified cotton seed. ($1 = 5.1673 reais)

(Reporting by Ana Mano; Editing by Sandra Maler)

https://www.marketscreener.com/quote/st ... -43022995/

[nobody]

Winst chemiebedrijf Bayer omhoog door duurdere onkruidbestrijding

LEVERKUSEN (ANP/AFP) - Hoge prijzen voor en sterke vraag naar onkruidbestrijdingsmiddelen op basis van het omstreden middel glyfosaat, hebben chemiebedrijf Bayer aan flink hogere winsten geholpen. Omdat er tekorten waren aan die middelen, zoals het bekende Roundup, kon Bayer er veel meer geld voor vragen.

De bestrijdingsmiddelen waren de aanjager van een sterke groei bij de landbouwtak van het bedrijf. De farmaceutische tak groeide nauwelijks, maar de divisie die geneesmiddelen maakt die zonder doktersrecept te krijgen zijn deed wel goede zaken. Er was in 2022 veel vraag naar middelen tegen allergieën en verkoudheid.

Alles bij elkaar steeg de omzet met 8,7 procent tot 50,7 miljard euro. Onder de streep bleef daar 4,2 miljard euro van over, ruim vier keer zoveel als de 1 miljard euro winst uit 2021.

Topman Werner Baumann van Bayer vertrekt deze zomer onder druk van een aantal investeerders. Hij wordt vervangen door oud-Roche-bestuurder Bill Anderson. Diezelfde investeerders zouden ook graag zien dat Bayer gesplitst wordt in een bedrijf dat zich richt op landbouw en een farmaceutisch bedrijf. Critici menen dat dat laatste onderdeel te klein is en direct een overnameprooi wordt.

https://www.msn.com/nl-nl/geldzaken/nie ... af57&ei=26

[Karl]

Barclays herhaalt het koopadvies voor BAYER AG NA O.N.
woensdag 1 maart 2023 - 06:36u -

Het koopadvies van vrijdag 10 februari 2023 wordt herhaald. Dit vorige advies heeft geresulteerd in een rendement van -5,77%.

Koersdoel €80.